Cannabis topicals occupy a unique position in the cannabinoid product landscape. They are the entry point for consumers who are interested in cannabis therapeutics but hesitant about psychoactive effects. They are the product category with some of the most aggressive marketing claims and some of the least substantiated efficacy data. And they operate in a space where the fundamental pharmacology — whether cannabinoids applied to the skin can reach their targets in meaningful concentrations — is more complicated than most consumers realize.

The cannabis topical market was valued at approximately $1.6 billion in 2024 and is projected to grow to $4.2 billion by 2030, according to Grand View Research. This growth is driven by consumer demand for localized pain relief, anti-inflammatory therapy, and skincare applications — and by a marketing ecosystem that sometimes promises more than the science can deliver.

Understanding what cannabis topicals can and cannot do requires understanding what happens when you rub a cannabinoid on your skin.

The Skin Barrier: Why Delivery Matters More Than Dose

Human skin is an exceptionally effective barrier. Its primary biological function is to keep things out — pathogens, chemicals, water, UV radiation — and it has evolved over millions of years to be very good at this job. The outermost layer of skin, the stratum corneum, is a 10- to 15-micrometer-thick layer of dead, flattened cells (corneocytes) embedded in a lipid matrix. This structure functions like a brick-and-mortar wall, with the corneocytes as bricks and the lipid matrix as mortar.

Any substance applied to the skin surface must penetrate this barrier to reach living tissue where it can exert therapeutic effects. The physics and chemistry of this penetration determine whether a topical product works or is simply expensive moisturizer.

THC and CBD are lipophilic molecules with relatively large molecular weights (THC: 314 g/mol, CBD: 314 g/mol). Their lipophilicity means they interact favorably with the lipid matrix of the stratum corneum — they dissolve into the barrier rather than being repelled by it. However, their molecular size and high lipophilicity create a paradox: while they enter the stratum corneum readily, they tend to accumulate there rather than passing through into the deeper living tissue layers (dermis and subcutaneous tissue).

This pharmacokinetic reality defines the fundamental challenge of cannabis topicals and creates the critical distinction between topical and transdermal delivery.

Topical vs. Transdermal: The Essential Distinction

These two terms are frequently confused in marketing materials, and the distinction between them determines what a product can realistically accomplish.

Topical products are designed to deliver cannabinoids to the skin itself and to the immediately underlying tissue — the epidermis, dermis, and superficial subcutaneous layer. They are not designed to deliver cannabinoids into the systemic bloodstream in significant quantities. A true topical works locally: it affects the area where it is applied and does not produce whole-body effects. THC topicals do not produce a psychoactive high because the THC does not reach the bloodstream in meaningful concentrations.

Transdermal products are specifically designed to push cannabinoids through the skin and into the systemic bloodstream, where they distribute throughout the body. Transdermal delivery uses chemical penetration enhancers, specialized vehicle formulations, or physical delivery mechanisms (patches, microneedles) to overcome the barrier that stops topical products. A transdermal THC product can produce psychoactive effects because THC reaches the blood and subsequently the brain.

This distinction matters enormously for consumers. If you want localized relief at a specific joint or muscle, you want a topical. If you want systemic cannabinoid effects delivered through the skin rather than through inhalation or ingestion, you want a transdermal product. Many products on the market blur this distinction in their marketing, implying transdermal delivery without using transdermal technology.

What Happens When You Apply a Cannabis Topical

When you rub a CBD cream or THC balm onto your skin, the following process occurs:

Phase 1: Vehicle interaction. The cream, lotion, or balm base (the vehicle) spreads across the skin surface and begins to interact with the stratum corneum. The vehicle composition determines how effectively it delivers cannabinoids to the barrier. Oil-based vehicles (balms, salves) tend to occlude the skin surface, increasing hydration of the stratum corneum and temporarily enhancing permeability. Water-based vehicles (lotions, creams) spread more easily but may be less effective at driving lipophilic compounds into the barrier.

Phase 2: Partitioning into the stratum corneum. Cannabinoids migrate from the vehicle into the lipid matrix of the stratum corneum. This occurs relatively quickly — within minutes of application. The stratum corneum acts as a reservoir, accumulating cannabinoids over the first 30 to 60 minutes.

Phase 3: Diffusion into deeper layers. From the stratum corneum reservoir, cannabinoids slowly diffuse into the viable epidermis and dermis. This is where the process slows dramatically. Permeation studies have shown that only a fraction of the applied cannabinoid dose reaches the dermis. A 2004 study published in the journal Molecules quantified that less than 10% of topically applied CBD penetrated beyond the stratum corneum in an in vitro human skin model over 24 hours.

Phase 4: Local tissue distribution. Cannabinoids that reach the dermis and subcutaneous tissue encounter cannabinoid receptors (CB1 and CB2), TRPV1 receptors (vanilloid receptors involved in pain signaling), and immune cells with endocannabinoid system components. This is where therapeutic effects can occur — but only if sufficient cannabinoid concentrations are achieved in the target tissue.

Phase 5 (limited for topicals): Systemic absorption. Some cannabinoid that reaches the dermis will enter capillaries and the bloodstream. For standard topical formulations, this systemic absorption is minimal — typically undetectable in blood tests. For transdermal formulations with penetration enhancers, systemic absorption is the intended outcome.

The Bioavailability Problem

Bioavailability — the percentage of an administered dose that reaches its target in active form — is the central challenge of cannabis topicals.

For inhaled cannabis, bioavailability is approximately 30% to 50%. For oral cannabis (edibles), bioavailability is approximately 6% to 20%. For topical cannabis, bioavailability at the target tissue (dermis and subcutaneous tissue directly beneath the application site) has been estimated at approximately 1% to 5% of the applied dose, based on in vitro permeation studies.

This means that if you apply a cream containing 100 mg of CBD to your knee, approximately 1 to 5 mg of CBD may actually reach the tissue beneath the skin at that location. The rest remains in the stratum corneum (where it may have some local effect), on the skin surface (where it washes off), or is metabolized before reaching target receptors.

This low bioavailability raises a straightforward question: is 1 to 5 mg of CBD at a local tissue site sufficient to produce a therapeutic effect?

The answer depends on the concentration of cannabinoid receptors in the target tissue, the specific condition being treated, and individual factors including skin thickness, hydration, and local blood flow. For skin conditions where the target is the epidermis and superficial dermis — the layers that topically applied cannabinoids reach most easily — the effective concentrations may be achievable. For conditions affecting deeper structures — joint capsules, deep muscle tissue, tendons, nerve bundles — the concentrations reaching those depths are substantially lower and may be subtherapeutic.

The Evidence for Pain and Inflammation

Localized Pain

The evidence for cannabis topicals in localized pain management is a mix of mechanistically plausible pharmacology, limited clinical data, and extensive consumer reports.

The mechanistic case is sound. The skin contains CB1 and CB2 receptors, as do the peripheral sensory neurons that transmit pain signals. TRPV1 receptors — which play a key role in pain and temperature sensation — are expressed in skin and are modulated by both CBD and THC. Immune cells in the skin and subcutaneous tissue have endocannabinoid system components that regulate local inflammatory responses.

A 2016 preclinical study published in the European Journal of Pain examined transdermal CBD application in a rat model of arthritis. CBD gel applied to the skin over arthritic joints reduced joint swelling, limb posture scores (a measure of pain-related behavior), and immune cell infiltration in a dose-dependent manner. Pro-inflammatory cytokine levels (TNF-alpha) in the affected tissue were reduced. This study is frequently cited as evidence for topical CBD efficacy, but it used a transdermal gel formulation with penetration enhancers in rats — conditions that do not directly translate to a consumer applying a standard CBD cream to human skin.

A 2020 randomized controlled trial published in Postgraduate Medicine examined a transdermal CBD formulation in 29 patients with symptomatic peripheral neuropathy of the lower extremities. The CBD group reported statistically significant reductions in pain intensity and other neuropathy symptoms compared to placebo over an 8-week treatment period. However, this study used a specifically engineered transdermal formulation, not a standard topical cream.

A 2022 study in the Journal of Pain Research examined a topical CBD product (containing 250 mg CBD per ounce) in 54 patients with temporomandibular joint (TMJ) disorder. After 2 weeks of twice-daily application, the CBD group showed statistically significant improvements in jaw pain and function compared to placebo. This study is more relevant to the average consumer because it used a standard topical formulation rather than an engineered transdermal delivery system.

Arthritis

Arthritis — the condition most commonly cited in cannabis topical marketing — has limited direct clinical evidence for topical cannabinoid efficacy.

The rat study mentioned above (Hammell et al., 2016) is the primary preclinical reference. In human studies, a 2022 observational study in the journal Musculoskeletal Care surveyed 428 arthritis patients who used topical CBD products and found that 83% reported improvement in pain, 66% reported improvement in physical function, and 44% reported reduced need for other medications. However, this was a survey of self-selected users (people who chose to use and continue using topical CBD), not a controlled trial, and placebo effects in topical pain treatments are substantial.

No large, randomized, placebo-controlled trial of topical cannabis for human arthritis has been published as of early 2026. This is a significant gap given that arthritis is the primary marketing target for cannabis topical products.

Skin Conditions

For skin conditions — where the target tissue is the epidermis and superficial dermis — topical cannabinoids are on somewhat firmer pharmacological ground because the target is more accessible.

A 2019 study published in La Clinica Terapeutica examined a CBD-enriched ointment applied to the skin of 20 patients with psoriasis, eczema, and scarring. After 3 months of twice-daily application, clinical parameters including hydration, transepidermal water loss, and elasticity showed significant improvement. The study lacked a placebo control, but the results are consistent with cannabinoid effects on epidermal biology.

CBD has demonstrated antiproliferative effects on keratinocytes (the primary cells of the epidermis) in cell culture studies, which is relevant to psoriasis — a condition characterized by excessive keratinocyte proliferation. CBD has also shown sebum-reducing effects on sebocytes (oil-producing cells) in vitro, which is relevant to acne. These preclinical findings have generated significant interest but have not yet been validated in rigorous clinical trials.

For eczema and dermatitis, cannabinoids may reduce local inflammation through CB2 receptor activation and cytokine modulation in the skin. The palmitoylethanolamide (PEA) pathway — an endocannabinoid-like lipid that modulates CB2 signaling — has shown efficacy in clinical trials for atopic dermatitis, suggesting that the broader endocannabinoid system plays a role in skin inflammatory conditions.

Product Types and Their Differences

The cannabis topical market offers a confusing array of product types. The differences matter for efficacy.

Creams and Lotions

Water-in-oil or oil-in-water emulsions that spread easily and absorb relatively quickly. These are the most common cannabis topical format. They provide moderate cannabinoid delivery to the stratum corneum and superficial dermis. Best for: covering larger areas, facial application, conditions affecting the skin surface (eczema, mild inflammation). Limitations: lower sustained release compared to balms; water content means some evaporation of vehicle before full absorption.

Balms and Salves

Oil-based or wax-based preparations without water content. They create an occlusive layer on the skin that increases stratum corneum hydration and may enhance cannabinoid penetration. They provide more sustained delivery than creams because the occlusive layer keeps cannabinoids in contact with the skin longer. Best for: targeted application to specific joints or muscles, conditions requiring sustained local exposure. Limitations: greasy texture, slower absorption, can stain clothing.

Transdermal Patches

Engineered delivery systems that use penetration enhancers and controlled-release technology to push cannabinoids through the skin into the bloodstream. Patches deliver cannabinoids systemically, not just locally. A THC transdermal patch will produce psychoactive effects (gradually and at lower peak intensity than smoking). Best for: sustained systemic cannabinoid delivery over 8 to 12 hours, medical patients requiring consistent blood levels. Limitations: higher cost, limited product availability, slower onset than inhalation or sublingual methods, potential skin irritation at the application site.

The technology behind effective transdermal patches is substantially more complex than other topical formats. Effective patches typically use permeation enhancers such as terpenes (limonene and cineole have demonstrated skin penetration enhancement in studies), oleic acid, or propylene glycol to disrupt the stratum corneum barrier. Some patches use iontophoresis (electrical current) or microneedle technology to physically bypass the barrier.

Roll-Ons and Gels

Similar to creams in their delivery characteristics but in a more convenient format for targeted application. Many gel formulations include menthol, camphor, or other counterirritant ingredients that produce immediate cooling or warming sensations. These sensations are produced by the counterirritant, not by the cannabinoid, and consumers should be aware that the immediate sensation of “it’s working” may reflect the menthol rather than the CBD.

Bath Bombs and Soaks

Cannabis-infused bath products dissolve in water, creating a dilute cannabinoid solution that contacts the entire body. The pharmacological plausibility of bath bombs is questionable. Cannabinoids are lipophilic and do not dissolve well in water. Even with emulsifiers, the concentration of cannabinoids in a full bathtub of water is extremely low. The surface area of skin exposure is large, but the concentration gradient driving penetration is minimal. Any relaxation benefits from a cannabis bath bomb are likely attributable to the warm water, essential oils, and placebo effect rather than meaningful cannabinoid absorption. Some bath products include Epsom salt (magnesium sulfate), which has its own mild muscle-relaxing properties that may contribute to perceived effects.

Separating Efficacy from Marketing

The cannabis topical market is rife with overclaiming, and consumers deserve honest guidance on which claims have scientific support and which are primarily marketing.

Claims with reasonable scientific support:

  • CBD topicals may reduce localized pain and inflammation in superficial tissues when applied directly to the affected area at sufficient concentrations.
  • CBD topicals may benefit certain skin conditions (eczema, psoriasis, acne) through direct effects on epidermal and dermal cells.
  • Transdermal patches can deliver cannabinoids systemically through the skin.
  • Topical THC does not produce a psychoactive high (when using non-transdermal formulations).

Claims with limited or no scientific support:

  • Topical CBD reaches deep joint tissue in therapeutic concentrations through standard cream formulations. The bioavailability data does not support significant penetration to deep joint structures through a cream applied to the overlying skin.
  • Cannabis topicals provide “full-body” pain relief. By definition, topical (non-transdermal) products work locally, not systemically.
  • Higher milligram counts on the label mean better effects. A product with 1,000 mg of CBD in a 4-ounce jar delivers approximately 8 mg per application (assuming a pea-sized amount), and only a fraction of that reaches target tissue. The total milligrams in the jar are less important than the per-application dose and the formulation’s ability to deliver it.
  • Cannabis-infused bath products provide meaningful cannabinoid therapy. The dilution and delivery limitations make pharmacologically significant absorption extremely unlikely.

The menthol and capsaicin factor. Many cannabis topicals contain menthol, camphor, capsaicin, arnica, or other ingredients with established topical analgesic effects. These ingredients provide real, immediate sensory effects (cooling, warming, tingling) that consumers perceive as the product “working.” In some formulations, the non-cannabinoid ingredients may be providing the majority of the perceived benefit. This is not inherently deceptive — a product that provides pain relief is useful regardless of which ingredient is responsible — but consumers should be aware that the cannabis component may not be the primary active agent in their topical.

Formulation Quality: What to Look For

Not all cannabis topicals are formulated with equal care or pharmacological sophistication. Quality indicators include:

Nano-emulsion or liposomal technology. Some higher-end topicals use nanotechnology to reduce cannabinoid particle size, potentially improving skin penetration. Liposomal formulations encapsulate cannabinoids in lipid vesicles that may enhance delivery across the stratum corneum. These technologies add cost but have some preclinical support for improved bioavailability.

Appropriate cannabinoid concentration. Look for products that provide at least 5 to 10 mg of cannabinoid per typical application. Products with very low total cannabinoid content (under 100 mg in a large container) may not deliver meaningful doses per application.

Third-party testing. As with all cannabis products, a Certificate of Analysis from an independent lab confirms cannabinoid content and screens for contaminants. This is the minimum quality threshold.

Complementary ingredients. Products that combine cannabinoids with other ingredients having evidence for topical efficacy — menthol, camphor, arnica, capsaicin, hyaluronic acid (for skincare applications) — may provide additive benefits.

The Bottom Line

Cannabis topicals occupy a scientifically plausible but clinically underproven therapeutic niche. The mechanisms are real — cannabinoid receptors exist in the skin, and cannabinoids interact with pain and inflammatory pathways in peripheral tissue. The challenge is delivery: getting sufficient cannabinoid concentrations to the right tissue depth through an organ designed to keep molecules out.

For skin-surface conditions — inflammatory skin diseases, acne, superficial wound healing — the evidence is most promising because the target tissue is most accessible.

For localized musculoskeletal pain — the primary consumer use case — the evidence is suggestive but limited by the bioavailability challenge. Topicals may provide benefit for superficial pain sources, but expectations should be calibrated by the pharmacological reality that standard topical formulations do not deliver large concentrations to deep tissue structures.

For systemic effects, transdermal patches with engineered penetration technology are the only topical format with pharmacological credibility, and they represent a fundamentally different product category from creams and balms.

The honest consumer guidance is this: cannabis topicals are worth trying for localized pain and skin conditions, they are low-risk (minimal side effects, no psychoactive effects from non-transdermal formulations), and they should be evaluated based on your personal experience over 1 to 2 weeks of consistent use rather than based on label claims or marketing promises. If they work for you, the mechanism does not matter as much as the outcome. If they do not work, the science suggests that increasing the dose (applying more product) is unlikely to overcome the fundamental delivery limitations — and you may be better served by a different route of cannabinoid administration.